News headlines about Chembio Diagnostics (NASDAQ:CEMI) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chembio Diagnostics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.7632385297146 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Separately, ValuEngine raised shares of Chembio Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th.
Chembio Diagnostics (NASDAQ:CEMI) opened at $7.25 on Tuesday. Chembio Diagnostics has a 12 month low of $5.05 and a 12 month high of $7.25. The company has a quick ratio of 2.19, a current ratio of 3.54 and a debt-to-equity ratio of 0.01.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/chembio-diagnostics-cemi-earns-news-impact-score-of-0-20.html.
About Chembio Diagnostics
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.